tocilizumab – Medxy AI

Tocilizumab Reduces Major Cardiovascular Events Risk in Giant Cell Arteritis: Insights from a Nationwide French Cohort

By MedXY 09/08/2026

A nationwide observational study reveals tocilizumab use in giant cell arteritis significantly lowers major adverse cardiovascular events compared to methotrexate, highlighting its potential cardiovascular benefits beyond inflammation control.

Allergy & Immunology Neurology news

Interleukin 6 Receptor Blockade: A Promising Strategy for Relapse Prevention in MOG Antibody-Associated Disease

By MedXY 07/16/2026

IL-6 receptor blockade significantly reduces relapse rates in MOG antibody-associated disease, showing comparable efficacy to high-dose IVIG with a favorable safety profile, supporting its role in relapse prevention.

news Psychiatry Public Health

Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial

By MedXY 06/03/2026

A small randomized trial found that blocking IL-6 with tocilizumab showed promising, clinically meaningful trends for inflammation-related, hard-to-treat depression, especially for somatic symptoms, fatigue, anxiety, and quality of life, though results were not statistically significant.

Diabetes & Endocrinology news Ophthalmology

Tocilizumab Shows Promising Benefits in Glucocorticoid-Resistant Thyroid Eye Disease

By MedXY 05/13/2026

In two prospective cohorts of active, glucocorticoid-resistant thyroid eye disease, tocilizumab improved eye inflammation, proptosis, diplopia, and quality of life with acceptable safety, supporting IL-6 blockade as a promising second-line treatment.